EA201990392A1 - Процесс получения композиций иммуноглобулинов - Google Patents

Процесс получения композиций иммуноглобулинов

Info

Publication number
EA201990392A1
EA201990392A1 EA201990392A EA201990392A EA201990392A1 EA 201990392 A1 EA201990392 A1 EA 201990392A1 EA 201990392 A EA201990392 A EA 201990392A EA 201990392 A EA201990392 A EA 201990392A EA 201990392 A1 EA201990392 A1 EA 201990392A1
Authority
EA
Eurasian Patent Office
Prior art keywords
immunoglobulin
igg
enriched
compositions
igm
Prior art date
Application number
EA201990392A
Other languages
English (en)
Inventor
Оливер МАНЕГ
Ахим Ханнаппель
Александер Мёленкамп-Рёттгер
Вольфганг Мёллер
Дитер РУДНИК
Original Assignee
Биотест Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Биотест Аг filed Critical Биотест Аг
Publication of EA201990392A1 publication Critical patent/EA201990392A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/30—Extraction; Separation; Purification by precipitation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Настоящее изобретение относится к способу получения фармацевтически приемлемых композиций иммуноглобулинов из полученных из плазмы фракций иммуноглобулинов, позволяющему параллельное получение композиций иммуноглобулинов, обогащенных IgG, IgM и IgA. По этому способу иммуноглобулин, содержащийся в фракции Кона I/II/III или фракции Кистлера/Нитшманна A+I, ресолюбилизируют при проводимости по меньшей мере 1 мСм/см и после удаления загрязняющего белка ресолюбилизированный иммуноглобулин подвергают анионообменной хроматографии для получения обогащенных IgG и IgM/IgA композиций иммуноглобулинов. Обогащенную IgG композицию иммуноглобулинов дополнительно подвергают обработке с использованием катионообменного материала для получения композиции иммуноглобулинов, имеющей уменьшенное содержание пропердина.
EA201990392A 2016-07-27 2017-07-26 Процесс получения композиций иммуноглобулинов EA201990392A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16181493.4A EP3275897A1 (en) 2016-07-27 2016-07-27 Process for preparing immunoglobulin compositions
PCT/EP2017/068914 WO2018019898A1 (en) 2016-07-27 2017-07-26 Process for preparing immunoglobulin compositions

Publications (1)

Publication Number Publication Date
EA201990392A1 true EA201990392A1 (ru) 2019-07-31

Family

ID=56555240

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201990392A EA201990392A1 (ru) 2016-07-27 2017-07-26 Процесс получения композиций иммуноглобулинов

Country Status (10)

Country Link
US (2) US11325964B2 (ru)
EP (2) EP3275897A1 (ru)
JP (1) JP7073333B2 (ru)
CN (1) CN109641950B (ru)
AU (1) AU2017302006B2 (ru)
BR (1) BR112019000736A2 (ru)
CA (1) CA3031462A1 (ru)
EA (1) EA201990392A1 (ru)
MA (1) MA45768A (ru)
WO (1) WO2018019898A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160257754A1 (en) 2013-10-16 2016-09-08 Momenta Pharmaceuticals Inc. Sialylated glycoproteins
CN109575129B (zh) * 2018-12-29 2022-04-26 贵州泰邦生物制品有限公司 一种静注人免疫球蛋白的制备工艺
KR20230024885A (ko) * 2020-04-10 2023-02-21 플라즈마 테크놀로지스, 엘엘씨 간소화된 고효율 단백질 단리를 위한 조성물 및 방법 (compositions and methods for simplified high efficiency isolation of proteins)
JP2024501025A (ja) * 2020-12-28 2024-01-10 プラズマ テクノロジーズ エルエルシー 免疫グロブリンｇのプロセススケールでの単離のためのシステム及び方法
AU2022317368A1 (en) * 2021-07-29 2024-02-22 Csl Behring Ag Method of purifying immunoglobulin g and uses thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4296027A (en) 1977-08-31 1981-10-20 The Regents Of The University Of Minnesota Pure intravenous human and animal gamma globulins
US4136094A (en) 1977-08-31 1979-01-23 The Regents Of The University Of Minnesota Preparation of intravenous human and animal gamma globulins and isolation of albumin
DE2901822A1 (de) 1979-01-18 1980-07-31 Biotest Serum Institut Gmbh Verfahren zur herstellung einer fuer die intravenoese applikation geeigneten immunglobulinloesung, die igm in ankonzentrierter form enthaelt
SU1137098A1 (ru) * 1983-07-21 1985-01-30 Московская ветеринарная академия им.К.И.Скрябина Способ выделени пропердина из сыворотки крови
IL90281A (en) 1988-06-06 1994-10-07 Miles Inc Preparations containing MGI antibodies
DE3825429C2 (de) 1988-07-27 1994-02-10 Biotest Pharma Gmbh Verfahren zur Herstellung eines intravenös verabreichbaren polyklonalen Immunglobulin-Präparates mit hohem IgM-Gehalt
DE3927112C1 (ru) 1989-08-17 1990-10-25 Biotest Pharma Gmbh, 6072 Dreieich, De
DE3927111C3 (de) 1989-08-17 1994-09-01 Biotest Pharma Gmbh Verfahren zur Herstellung nicht modifizierter intravenös verabreichbarer IgM- und/oderIgA-haltiger Immunglobulinpräparate
ATE122054T1 (de) 1990-03-22 1995-05-15 Biotest Pharma Gmbh Verfahren zur herstellung eines intravenös verträglichen immunglobulin-g-präparates.
US5256771A (en) 1990-04-03 1993-10-26 Miles Inc. Heat treatment of IgM-containing immunoglobulins to eliminate non-specific complement activation
FI952196A0 (fi) 1995-05-08 1995-05-08 Suomen Punainen Risti Veripalv Framstaellning av immunoglobulin
TW491855B (en) 1996-08-07 2002-06-21 Csl Ltd Purification of immunoglobulins
ATE335511T1 (de) * 1997-08-26 2006-09-15 Amgen Fremont Inc Ein verfahren zur inhibierung der komplementaktivierung über einen alternativen weg
US5854051A (en) * 1997-09-15 1998-12-29 Heska Corporation Parasitic helminth asparaginase proteins, nucleic acid molecules, and uses thereof
ES2527915T3 (es) * 1998-06-09 2015-02-02 Csl Behring Ag Producto de inmunoglobulina G (IgG) líquido
AU753468B2 (en) * 1998-06-09 2002-10-17 Csl Behring Ag Process for producing immunoglobulins for intravenous administration and other immunoglobulin products
FR2824568B1 (fr) * 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
US6593744B2 (en) * 2001-11-20 2003-07-15 Koninklijke Philips Electronics, N.V. Multi-channel RF cable trap for magnetic resonance apparatus
SG176256A1 (en) * 2009-05-27 2012-01-30 Baxter Int A method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
IT1397061B1 (it) 2009-12-28 2012-12-28 Kedrion Spa Nuovo processo di purificazione su scala industriale di gammaglobuline da plasma umano per uso industriale.
GB201006753D0 (en) 2010-04-22 2010-06-09 Biotest Ag Process for preparing an immunolobulin composition
AU2010202125B1 (en) * 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
IL212911A0 (en) * 2011-05-16 2011-07-31 Omrix Biopharmaceuticals Ltd Immunoglobulin reduced in thrombogenic contaminants and preparation thereof
KR20140064768A (ko) * 2011-07-01 2014-05-28 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 항-프로퍼딘 항체 및 그의 용도
AR087953A1 (es) * 2011-08-26 2014-04-30 Baxter Int Metodo para reducir el potencial tromboembolico de una composicion de inmunoglobulina derivada de plasma
SG10201701224UA (en) * 2012-03-12 2017-04-27 Merck Patent Gmbh Removal of protein aggregates from biopharmaceutical preparations in a flowthrough mode
AU2013203043B2 (en) * 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
CN105358571B (zh) * 2013-07-01 2019-03-05 瑞士杰特贝林生物制品有限公司 方法
FR3018450B1 (fr) * 2014-03-11 2016-04-15 Lab Francais Du Fractionnement Procede de preparation de proteines plasmatiques humaines
ES2769783T3 (es) * 2014-03-11 2020-06-29 Green Cross Holdings Corp Procedimiento de purificación de inmunoglobulina
CN104402993B (zh) * 2014-11-28 2017-01-04 贵州泰邦生物制品有限公司 一种制备静注人免疫球蛋白的方法

Also Published As

Publication number Publication date
AU2017302006B2 (en) 2024-07-25
MA45768A (fr) 2019-06-05
EP3275897A1 (en) 2018-01-31
US20190161533A1 (en) 2019-05-30
US20220227841A1 (en) 2022-07-21
WO2018019898A1 (en) 2018-02-01
US11325964B2 (en) 2022-05-10
CN109641950A (zh) 2019-04-16
BR112019000736A2 (pt) 2019-05-07
EP3491018A1 (en) 2019-06-05
JP2019525933A (ja) 2019-09-12
AU2017302006A1 (en) 2019-01-24
CN109641950B (zh) 2023-06-02
CA3031462A1 (en) 2018-02-01
JP7073333B2 (ja) 2022-05-23

Similar Documents

Publication Publication Date Title
EA201990392A1 (ru) Процесс получения композиций иммуноглобулинов
MX2018002068A (es) Purificacion de fkpa y usos de la misma para producir polipeptidos recombinantes.
EA201890039A1 (ru) Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения
MD4716C1 (ru) Антитела анти-LAG3 и антигенсвязывающие фрагменты
EA201791590A1 (ru) Антитела к tau и их применение
EA201891732A1 (ru) Биспецифичные связывающие белки для pd-l1 и kdr
EA201892548A1 (ru) Антитела к альфа-синуклеину и их применение
GEP20227392B (en) Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same
MX2020000288A (es) Cromatografia.
MX2018009331A (es) Metodos para extraer proteinas a partir de un material a base de sangre.
EA201892225A1 (ru) АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ
MX2018016121A (es) Preparacion de anticuerpos monoclonales marcados con 212pb.
EA202092125A1 (ru) Антитела против рецептора фолата 1 и их применения
PH12017502020A1 (en) Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
NZ754676A (en) Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
EA202190807A1 (ru) Антитела к синуклеину
EA201990998A1 (ru) Фармацевтические составы и способы их получения
EA202090084A1 (ru) Новый терапевтический ферментный слитый белок и его применение
MY183011A (en) Novel purification process of gonadotropin
EA202091340A1 (ru) Способ получения соединений "лекарственное средство-линкер"
MX2023013392A (es) Anticuerpos para tratar alfa-sinucleinopatias.
MX2016012620A (es) Anticuerpos contra atigeno de plaqueta 1a humano (hpa-1a).
NZ742210A (en) Neospora vaccine composition
ZA202002083B (en) Antibody purification
MX2023007516A (es) Metodos de purificacion de proteinas de fusion con proteccion de carga.